Securities Report – 206th Fiscal Period (2025/04/01 – 2026/03/31)

Sumitomo Pharma Co., Ltd. Securities Report – 206th Fiscal Period (2025/04/01 – 2026/03/31)

Sumitomo Pharma Co., Ltd. has submitted its Securities Report for the 206th fiscal period (April 1, 2025 to March 31, 2026) to the Financial Services Agency. This report aims to provide investors and stakeholders with timely and accurate information regarding the company's management status, financial position, performance trends, and future outlook.

The company's core business encompasses research and development, manufacturing, and marketing of pharmaceutical products. Committed to delivering high-quality medicines that meet global healthcare needs, Sumitomo Pharma strives to create social value through innovation in medical treatment and patient care. The report includes detailed disclosures on consolidated and individual financial statements, management policies, risk factors, executive compensation, and share-related information.

Furthermore, the company emphasizes robust corporate governance, strengthened internal controls, and alignment with Sustainable Development Goals (SDGs) as key pillars of its long-term strategy. Sumitomo Pharma remains dedicated to enhancing corporate value sustainably and maintaining transparent communication with shareholders and investors.

The full report is available on the company's official website and the Financial Services Agency's EDINET (Electronic Disclosure for Investors' NETwork) system.